Previous Page
28
nanotimes
Companies Facts
MagForce has revised its corporate strategy to put more emphasis on clinical development and its synergies with Marketing and Sales. The company has received EU approval for its technology, Nano- Therm®
• US$1m milestone payment for achieving speci- fication targets for green quantum dots including a 50,000 hour performance life;
therapy, for the treatment of brain tumors.
Product revenues in 2011 were lower than expected due to the lack of involvement among leading me- dical experts in the development of the therapy. MagForce is now working closely with these key opinion leaders who have agreed to participate in a post-approval multi-center study to validate the novel technology in the medical community and gain first-hand experience.
“Our successful capital increase earlier this month along with reductions in expenditures will allow us to initiate both a glioblastoma post-market authori- zation study along with a study in prostate carcino- ma this year. These upcoming trials, conducted in centers throughout Germany, will lay the foundation for wider acceptance of the therapy and expanded commercial use,” said Dr. Andreas Jordan, Manage- ment Board and founder of MagForce. “In addition, we are in discussion with international companies and investors for strategic partnerships to share in the development costs and support international market approvals, including for the US market.”
anoco Group plc (AIM: NANO), a developer and manufacturer of cadmium-free quantum
dots and other nanomaterials, announced its interim results for the six months ended 31 January 2012. Highlights in the period to date:
• Joint development agreement signed with one of the world’s largest lighting companies for use of Nanoco quantum dots in general lighting;
• Further agreement signed with Tokyo Electron in the next phase of development of a nanomaterial- based solar film;
• Joint development agreement signed with major Asian electronics company for the use of Nanoco quantum dots in the LED backlighting of LCD displays;
• Manufacturing scale-up continued with planning permission granted for the Kilo Lab facility at Runcorn;
• Cash, cash equivalents and deposits as at January 31, 2012 of £14.4 million (July 31, 2011: £17.1 million).
Commenting on the results, Dr Peter Rowley, Nanoco’s Chairman, said: “Our transition from a research-based company to a commercially focused, high-tech manufacturing business continues apace. Our existing commercial agreements are proceeding well and we continue in discussions with further potential customers. We are now working to deliver a 1kg batch of green quantum dots to a Japanese customer, attracting a US$2 million milestone pay- ment.”
12-03 :: March/April 2012